Cumberland Pharmaceuticals (CPIX) Competitors

Cumberland Pharmaceuticals logo
$5.58 +0.37 (+7.10%)
As of 12:28 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CPIX vs. SPRY, TLRY, FENC, AVIR, and ENTA

Should you buy Cumberland Pharmaceuticals stock or one of its competitors? Cumberland Pharmaceuticals's main competitors and comparable companies include ARS Pharmaceuticals (SPRY), Tilray Brands (TLRY), Adherex Technologies (FENC), Atea Pharmaceuticals (AVIR), and Enanta Pharmaceuticals (ENTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cumberland Pharmaceuticals compare to ARS Pharmaceuticals?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Cumberland Pharmaceuticals has a net margin of 274.38% compared to ARS Pharmaceuticals' net margin of -163.64%. Cumberland Pharmaceuticals' return on equity of -31.40% beat ARS Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Cumberland Pharmaceuticals274.38% -31.40% -9.38%
ARS Pharmaceuticals -163.64%-453.93%-71.62%

In the previous week, Cumberland Pharmaceuticals had 5 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 7 mentions for Cumberland Pharmaceuticals and 2 mentions for ARS Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 0.79 beat ARS Pharmaceuticals' score of 0.40 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cumberland Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ARS Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cumberland Pharmaceuticals has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Cumberland Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cumberland Pharmaceuticals$44.52M1.90-$2.84M$4.491.26
ARS Pharmaceuticals$84.28M4.41-$171.30M-$2.02N/A

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

ARS Pharmaceuticals has a consensus target price of $23.33, suggesting a potential upside of 531.65%. Given ARS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Cumberland Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cumberland Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ARS Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Cumberland Pharmaceuticals has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

Summary

Cumberland Pharmaceuticals beats ARS Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

Cumberland Pharmaceuticals has lower revenue, but higher earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Cumberland Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tilray Brands$915.45M0.38-$121.40M-$1.40N/A
Cumberland Pharmaceuticals$44.52M1.90-$2.84M$4.491.26

Tilray Brands has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market.

Tilray Brands currently has a consensus price target of $5.90, indicating a potential upside of 151.60%. Given Tilray Brands' stronger consensus rating and higher possible upside, equities analysts plainly believe Tilray Brands is more favorable than Cumberland Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tilray Brands
2 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.38
Cumberland Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Tilray Brands had 7 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 14 mentions for Tilray Brands and 7 mentions for Cumberland Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 0.79 beat Tilray Brands' score of 0.62 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tilray Brands
4 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cumberland Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cumberland Pharmaceuticals has a net margin of 274.38% compared to Tilray Brands' net margin of -16.91%. Tilray Brands' return on equity of -10.39% beat Cumberland Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Tilray Brands-16.91% -10.39% -7.38%
Cumberland Pharmaceuticals 274.38%-31.40%-9.38%

9.4% of Tilray Brands shares are held by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 1.6% of Tilray Brands shares are held by insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Tilray Brands beats Cumberland Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Adherex Technologies?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Adherex Technologies has a consensus price target of $17.25, indicating a potential upside of 30.75%. Given Adherex Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Adherex Technologies is more favorable than Cumberland Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cumberland Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Adherex Technologies
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.00

Cumberland Pharmaceuticals has higher earnings, but lower revenue than Adherex Technologies. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Adherex Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cumberland Pharmaceuticals$44.52M1.90-$2.84M$4.491.26
Adherex Technologies$66.37M7.00-$9.74M$0.011,319.30

Cumberland Pharmaceuticals has a beta of 0.16, meaning that its share price is 84% less volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market.

In the previous week, Adherex Technologies had 5 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 12 mentions for Adherex Technologies and 7 mentions for Cumberland Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 0.79 beat Adherex Technologies' score of 0.78 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cumberland Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Adherex Technologies
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cumberland Pharmaceuticals has a net margin of 274.38% compared to Adherex Technologies' net margin of 2.52%. Adherex Technologies' return on equity of 9.58% beat Cumberland Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Cumberland Pharmaceuticals274.38% -31.40% -9.38%
Adherex Technologies 2.52%9.58%5.08%

Summary

Adherex Technologies beats Cumberland Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Atea Pharmaceuticals?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Atea Pharmaceuticals has a consensus price target of $8.00, indicating a potential upside of 96.80%. Given Atea Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Atea Pharmaceuticals is more favorable than Cumberland Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cumberland Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Atea Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.33

15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are held by insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cumberland Pharmaceuticals has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Cumberland Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cumberland Pharmaceuticals$44.52M1.90-$2.84M$4.491.26
Atea PharmaceuticalsN/AN/A-$158.35M-$1.95N/A

In the previous week, Cumberland Pharmaceuticals had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 7 mentions for Cumberland Pharmaceuticals and 5 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.92 beat Cumberland Pharmaceuticals' score of 0.79 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cumberland Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Atea Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Cumberland Pharmaceuticals has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Cumberland Pharmaceuticals has a net margin of 274.38% compared to Atea Pharmaceuticals' net margin of 0.00%. Cumberland Pharmaceuticals' return on equity of -31.40% beat Atea Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Cumberland Pharmaceuticals274.38% -31.40% -9.38%
Atea Pharmaceuticals N/A -69.91%-61.22%

Summary

Cumberland Pharmaceuticals beats Atea Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Enanta Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Cumberland Pharmaceuticals had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 7 mentions for Cumberland Pharmaceuticals and 6 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.89 beat Cumberland Pharmaceuticals' score of 0.79 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Enanta Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Cumberland Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Enanta Pharmaceuticals currently has a consensus target price of $20.00, indicating a potential upside of 103.77%. Given Enanta Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Enanta Pharmaceuticals is more favorable than Cumberland Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enanta Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Cumberland Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Cumberland Pharmaceuticals has lower revenue, but higher earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Cumberland Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enanta Pharmaceuticals$65.32M4.38-$81.89M-$2.41N/A
Cumberland Pharmaceuticals$44.52M1.90-$2.84M$4.491.26

Cumberland Pharmaceuticals has a net margin of 274.38% compared to Enanta Pharmaceuticals' net margin of -96.89%. Cumberland Pharmaceuticals' return on equity of -31.40% beat Enanta Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Enanta Pharmaceuticals-96.89% -61.84% -20.70%
Cumberland Pharmaceuticals 274.38%-31.40%-9.38%

Enanta Pharmaceuticals has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market.

Summary

Enanta Pharmaceuticals and Cumberland Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Cumberland Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CPIX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CPIX vs. The Competition

MetricCumberland PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$83.59M$13.60B$7.74B$11.56B
Dividend YieldN/A2.58%2.46%4.43%
P/E Ratio1.2429.4234.1829.77
Price / Sales1.887.008.475.63
Price / Cash18.0815.7421.9322.50
Price / Book3.404.804.303.66
Net Income-$2.84M$2.88B$3.51B$392.03M
7 Day Performance5.28%-4.12%-5.42%-4.17%
1 Month Performance-22.28%-5.13%-4.57%-6.64%
1 Year Performance193.68%-7.61%-1.56%-7.16%

Cumberland Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CPIX
Cumberland Pharmaceuticals
1.5568 of 5 stars
$5.58
+7.1%
N/A+146.9%$83.59M$44.52M1.2493
SPRY
ARS Pharmaceuticals
2.3334 of 5 stars
$3.96
+10.8%
$23.33
+490.0%
-56.3%$397.60M$84.28MN/A206
TLRY
Tilray Brands
3.4842 of 5 stars
$2.62
-1.3%
$5.90
+125.6%
-78.3%$387.94M$210.48MN/A3,595
FENC
Adherex Technologies
4.7558 of 5 stars
$10.77
+1.8%
$17.00
+57.9%
+62.3%$377.29M$59.22MN/A35
AVIR
Atea Pharmaceuticals
2.9481 of 5 stars
$4.29
+2.0%
$7.00
+63.4%
+39.2%$343.30MN/AN/A55

Related Companies and Tools


This page (NASDAQ:CPIX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners